{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:27:12Z","timestamp":1758050832722,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T00:00:00Z","timestamp":1664064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cellimm.2022.104616","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T11:14:02Z","timestamp":1664277242000},"page":"104616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adoptive transfer of activated immune cells against solid tumors: A preliminary study"],"prefix":"10.1016","volume":"382","author":[{"given":"Panagiotis","family":"Parsonidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Beis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aggelos C.","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Papasotiriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2022.104616_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707468","article-title":"Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer","volume":"12","author":"Cheng","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cellimm.2022.104616_b0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.cellimm.2022.104616_b0015","doi-asserted-by":"crossref","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.cellimm.2022.104616_b0020","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200377","article-title":"Adoptive cell therapy: Living drugs against cancer","volume":"217","author":"Laskowski","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2022.104616_b0025","first-page":"100575","article-title":"Adoptive Cellular Transfer Immunotherapies for Cancer","volume":"32","author":"Parsonidis","year":"2022","journal-title":"Cancer Treat Res Commun."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104616_b0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2214\/AJR.11.7483","article-title":"Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST","volume":"198","author":"Nishino","year":"2012","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104616_b0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1742395312466903","article-title":"\u201cJust give me the best quality of life questionnaire\u201d: the Karnofsky scale and the history of quality of life measurements in cancer trials","volume":"9","author":"Timmermann","year":"2013","journal-title":"Chronic Illn."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104616_b0040","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"2-3","key":"10.1016\/j.cellimm.2022.104616_b0045","first-page":"35","article-title":"Cancer symptom response as an oncology clinical trial end point","volume":"3","author":"Bouchard","year":"2018","journal-title":"Expert Rev Qual Life Cancer Care."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104616_b0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/bja\/aen103","article-title":"Assessment of pain","volume":"101","author":"Breivik","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.cellimm.2022.104616_b0055","series-title":"the Reviewer\u2019s Guide to Quantitative Methods in the Social Sciences","first-page":"15","article-title":"Analysis of variance: Repeated-measures designs","author":"Lix","year":"2019"},{"key":"10.1016\/j.cellimm.2022.104616_b0060","first-page":"50","article-title":"A Brief Review of Independent, Dependent and One Sample t-test, International Journal of Applied Mathematics and Theoretical","volume":"4","author":"Gerald","year":"2018","journal-title":"Physics."},{"key":"10.1016\/j.cellimm.2022.104616_b0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/cc1820","article-title":"Statistics review 6: Nonparametric methods","volume":"6","author":"Whitley","year":"2002","journal-title":"Crit. Care"},{"key":"10.1016\/j.cellimm.2022.104616_b0070","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An Analysis of Variance Test for Normality (Complete Samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"10.1016\/j.cellimm.2022.104616_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.cellimm.2022.104616_b0080","first-page":"19","article-title":"The need to report effect size estimates revisited","volume":"21","author":"Tomczak","year":"2014","journal-title":"An overview of some recommended measures of effect size"},{"key":"10.1016\/j.cellimm.2022.104616_b0085","unstructured":"R Core Team, R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. (2020). https:\/\/www.r-project.org\/ (accessed July 7, 2022)."},{"key":"10.1016\/j.cellimm.2022.104616_b0090","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw."},{"key":"10.1016\/j.cellimm.2022.104616_b0095","unstructured":"A. Kassambara, ggpubr: \u2019ggplot2\u2019 Based Publication Ready Plots, (2020). https:\/\/cran.r-project.org\/package=ggpubr (accessed July 7, 2022)."},{"key":"10.1016\/j.cellimm.2022.104616_b0100","doi-asserted-by":"crossref","unstructured":"A. Kassambara, rstatix: Pipe-Friendly Framework for Basic Statistical Tests, (2019). https:\/\/cran.rproject.org\/package=rstatix (accessed July 7, 2022).","DOI":"10.32614\/CRAN.package.rstatix"},{"issue":"2","key":"10.1016\/j.cellimm.2022.104616_b0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2022.104616_b0110","doi-asserted-by":"crossref","unstructured":"A. Hoeben, E.A.J. Joosten, M.H.J. van den Beuken-van Everdingen, Personalized Medicine: Recent Progress in Cancer Therapy., Cancers (Basel). 13 (2021). https:\/\/doi.org\/10.3390\/cancers13020242.","DOI":"10.3390\/cancers13020242"},{"key":"10.1016\/j.cellimm.2022.104616_b0115","doi-asserted-by":"crossref","unstructured":"A. Sarivalasis, M. Morotti, A. Mulvey, M. Imbimbo, G. Coukos, Cell therapies in ovarian cancer., Ther Adv Med Oncol. 13 (2021) 17588359211008400. https:\/\/doi.org\/10.1177\/17588359211008399.","DOI":"10.1177\/17588359211008399"},{"issue":"2","key":"10.1016\/j.cellimm.2022.104616_b0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/pharmaceutics12020158","article-title":"Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells","volume":"12","author":"Calmeiro","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.cellimm.2022.104616_b0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cellimm.2022.104616_b0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option","volume":"6","author":"Rohaan","year":"2018","journal-title":"J. ImmunoTher. Cancer"},{"issue":"6","key":"10.1016\/j.cellimm.2022.104616_b0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2022.104616_b0140","doi-asserted-by":"crossref","unstructured":"G. Multhoff, S. Seier, S. Stangl, W. Sievert, M. Shevtsov, C. Werner, A.G. Pockley, C. Blankenstein, M. Hildebrandt, R. Offner, N. Ahrens, K. Kokowski, M. Hautmann, C. R\u00f6del, R. Fietkau, D. Lubgan, R. Huber, H. Hautmann, T. Duell, M. Molls, H. Specht, B. Haller, M. Devecka, A. Sauter, S.E. Combs, Targeted Natural Killer Cell\u2013Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial, Clinical Cancer Research. 26 (2020) 5368\u20135379. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1141.","DOI":"10.1158\/1078-0432.CCR-20-1141"},{"key":"10.1016\/j.cellimm.2022.104616_b0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jcyt.2020.12.002","article-title":"Generating natural killer cells for adoptive transfer: expanding horizons","volume":"23","author":"Kundu","year":"2021","journal-title":"Cytotherapy."},{"key":"10.1016\/j.cellimm.2022.104616_b0150","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","article-title":"The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease","volume":"30","author":"Hont","year":"2022","journal-title":"Mol. Ther."},{"issue":"07","key":"10.1016\/j.cellimm.2022.104616_b0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4236\/jct.2019.107041","article-title":"MUC1 Antigen-Specific CD8 T Lymphocytes Targeting MCF7 and MDA-MB-231 Human Breast Adenocarcinoma Cell Lines","volume":"10","author":"Parsonidis","year":"2019","journal-title":"J Cancer Ther."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104616_b0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/jomfp.JOMFP_121_20","article-title":"Can B- cell based immunotherapy be our new perspective to exit cancer?","volume":"24","author":"Thomas","year":"2020","journal-title":"Journal of Oral and Maxillofacial Pathology."},{"issue":"11","key":"10.1016\/j.cellimm.2022.104616_b0165","first-page":"2667","article-title":"Systematic Review of Available CAR-T Cell Trials around the World","volume":"14","author":"Barros","year":"2022","journal-title":"Systematic Review of Available CAR-T Cell Trials around the World, Cancers (Basel)"},{"key":"10.1016\/j.cellimm.2022.104616_b0170","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104616_b0175","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.21873\/anticanres.14871","article-title":"T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874922001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874922001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T23:09:59Z","timestamp":1757804999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874922001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S0008874922001411"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2022.104616","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive transfer of activated immune cells against solid tumors: A preliminary study","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2022.104616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104616"}}